Jason David Allen | UVA School of ...

Dr. Jason Allen, PhD

Claim this profile

University of Virginia

Studies Peripheral Artery Disease
Studies Peripheral Arterial Disease
7 reported clinical trials
15 drugs studied

Affiliated Hospitals

Image of trial facility.

University Of Virginia

Image of trial facility.

University Of Virginia; Kinesiology Labs

Clinical Trials Jason Allen, PhD is currently running

Image of trial facility.

Metformin

for Exercise Capacity

Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity. The main question this study looks to answer is: • Does metformin alter exercise capacity? Participants will: * Complete 5 exercise tests on a stationary bike. * Undergo a body composition test. * Take metformin and placebo. * Complete food and symptom logs. The researchers hypothesize that: • Metformin will reduce aerobic capacity.

Recruiting

2 awards

Phase 4

3 criteria

Image of trial facility.

Beetroot Juice

for Peripheral Arterial Disease

The BEET PAD Trial is a multi-centered double-blind randomized clinical trial designed to determine whether beetroot juice, compared to placebo, improves six-minute walk distance at four month follow-up in people with lower extremity peripheral artery disease (PAD). Investigators hypothesize that by simultaneously increasing lower extremity perfusion, gastrocnemius muscle mitochondrial activity, and myofiber health and regeneration, beetroot juice will significantly improve walking performance in people with PAD. The primary aim is to determine whether beetroot juice significantly improves six-minute walk distance at 4-month follow-up in people with PAD, compared to placebo. Preliminary evidence suggests that beetroot juice has both acute and chronic effects on walking performance in PAD. The primary outcome will measure the combined acute and chronic effect of beetroot juice (i.e. the maximal effect) on change in 6-minute walk at 4-month follow-up. In secondary aims, investigators will distinguish between acute and chronic effects of beetroot juice on six-minute walk and delineate biologic pathways by which beetroot juice improves walking performance in PAD, by measuring change in gastrocnemius muscle perfusion (MRI arterial spin labeling) and gastrocnemius muscle health. The trial will assess the durability of beetroot juice effects on six-minute walk. Nitrate in beetroot juice is metabolized to nitrite and subsequently to NO, attaining peak nitrite levels 2.5 hours after ingestion. The trial will determine whether a higher peak or a greater increase in plasma nitrite at 2.5 hours after beetroot juice consumption at baseline has a greater effect on six-minute walk at 4-month follow-up, compared to a lower peak or a smaller increase, respectively.

Recruiting

0 awards

N/A

5 criteria

More about Jason Allen, PhD

Clinical Trial Related

1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Jason Allen, PhD has experience with

  • COMBO
  • PRIME
  • Metformin
  • Beetroot Juice
  • Placebo
  • Home-Based Exercise

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jason Allen, PhD specialize in?

Is Jason Allen, PhD currently recruiting for clinical trials?

Are there any treatments that Jason Allen, PhD has studied deeply?

What is the best way to schedule an appointment with Jason Allen, PhD?

What is the office address of Jason Allen, PhD?

Is there any support for travel costs?